• br Experimental section br Acknowledgements This work was fu

  2025-01-07

  

  Experimental section Acknowledgements This work was funded by the Italian Association for Cancer Research (AIRC IG18590 to A.A.), by “Fondi di Ateneo-University of Pisa” years 2009 and 2010 (E. N., S. N., E. O., and A. R.) and partially by the Unipi project P.R.A.2016_27 (E. N., E.O. and A. R.

• An ALK rearrangement was found in

  2025-01-07

  

  An ALK rearrangement was found in all the analyzable ‘truly positive’ IHC+/FISH+ samples, and the proportion of the various transcripts was in accordance with the literature [[26], [46], [47], [48]]. In these samples, the RNA-seq technique was therefore 100% sensitive and specific. Additional non-ta

• While HTPCs are not immune

  2025-01-07

  

  While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o

• br Experimental section br Results and discussion br Conclus

  2025-01-07

  

  Experimental section Results and discussion Conclusions We present a simple, sensitive and selective assay of ADA activity and its inhibitor using the enzyme catalyzed reaction and the different interaction intensity of dye-labeled AD aptamer, aptamer/AD complex with GO. The as-proposed met

• Patients with AAG often respond to intravenous immunoglobuli

  2025-01-07

  

  Patients with AAG often respond to intravenous immunoglobulin or plasma exchange. If these therapies are inadequate, ongoing immune suppression with steroids, azathioprine, mycophenylate or rituximab have been shown to be effective in case reports. Our patient seemed initially resistant to steroid t

• Significant reductions in GYN cancer patient mortality

  2025-01-06

  

  Significant reductions in GYN cancer patient mortality and morbidity rates require treatments that proactively prevent and reverse resistance to chemotherapy and radiation. Combining chemotherapy and radiation with inhibitors of key DDR proteins targets is likely to enhance the ability of genotoxic

• br Conclusions In the current study we found

  2025-01-06

  

  Conclusions In the current study, we found that the exposure of maduramicin to chicken myocardial Ranolazine results in cellular damage and even death via the induction of apoptosis. Maduramicin upregulated the expression of apoptotic genes and activated caspase cascades, which were accompanied b

• br Acknowledgements This study was

  2025-01-06

  

  Acknowledgements This study was funded the Irish Department of Agriculture, Food and the Marine through the research program FIRM/RSF/CoFoRD (Reference: 13 F 462). The authors declare no conflict of interest. Introduction Radiotherapy (RT) is one of the major treatment methods among patients

• AMPK is an essential player in

  2025-01-04

  

  AMPK is an essential player in adiponectin signaling pathway that regulates energy metabolism. The fact that suppression of AMPK activity by compound C largely diminished candesartan-mediated inhibition of NFκB via blocking AT1 also suggests that the AT1-mediated effect is at least partly resulted f

• edu assay Derivatives of M that possess either an alkyne or

  2025-01-04

  

  Derivatives of (+)-M100907 that possess either an alkyne or an azide have been synthesized. The most active enantiomer was obtained by resolution of a relatively early intermediate in the synthesis. The ability of these edu assay to maintain 5-HTR antagonist properties as (+)-M100907 was demonstrat

• br Conflict of Interest br Transparency Document br Introduc

  2025-01-04

  

  Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is

• Interestingly a homolog of C elegans acr is

  2025-01-04

  

  Interestingly, a homolog of C. elegans acr-23 is present in the A. suum FDA-approved drug library (Jex et al., 2011). However, A. suum is not susceptible to monepantel treatment in vivo (Tritten et al., 2011). Our research seeks to advance knowledge on the mode of action of monepantel on nAChRs fro

• In contrast to TPX members of the

  2025-01-04

  

  In NF-κB pathway inhibitor to TPX2, members of the CPC (Figure 1B), such as survivin, borealin, and INCEN-P, which associate with Aurora B/C in animals, do not appear to have obvious homologs in plants. Recently, however, a putative INCEN-P homolog, termed WYRD, has been identified [34]. Sequence co

• IC values were obtained for an expanded version

  2025-01-04

  

  IC50 values were obtained for an expanded version of the fragment library using the previously described mobility shift assay. Subsequently, Ki values were estimated from IC50 values to allow better comparison of the activity against targets which were measured at different substrate concentrations

• Somatostatin analogs also bind to somatostatin

  2025-01-04

  

  Somatostatin analogs also bind to somatostatin receptors. It has been reported that octreotide has a high affinity for hSSTR2, moderate affinity for hSSTR3 and hSSTR5, and does not bind to hSSTR1 or hSSTR4 (Ben-Shlomo and Melmed 2008). Compared to octreotide, pasireotide displays 40-, 30-, and 5-fol

15175 records 25/1012 page Previous Next First page 上5页 2122232425 下5页 Last page